Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

Exclusion Criteria

• •1. Symptomatic or untreated central nervous system metastasis
• •2. Inadequate washout from prior anticancer therapy
• •3. Significant ongoing toxicity from prior anticancer treatment
• •4. Impaired baseline organ function as evaluated by out-of-range laboratory values
• •5. Clinically significant cardiac disease
• •6. Active infection requiring systemic antibiotic therapy
• •7. Known history of human immunodeficiency virus (HIV)
• •8. Active hepatitis B virus (HBV) or hepatitis C virus (HCV)
• •9. Ongoing treatment with systemic steroids or other immunosuppressive therapies
• •10. Significant secondary malignancy
• •11. Pregnancy or lactation